

IN THE CLAIMS

Pursuant to 37 C.F.R. § 1.121(c)(1-3), please cancel claim 5 and replace claims 1, 6 and 11 with claims 1, 6 and 11 set forth below.

- B16
1. (Amended) A method for targeting degradation of a polypeptide in vivo comprising:
providing a ubiquitin protein ligase polypeptide-target polypeptide interaction domain hybrid comprising a ubiquitin protein ligase polypeptide that encodes a ubiquitin conjugation activity, which is functionally linked to a target polypeptide interaction domain that provides a target polypeptide recruitment activity, wherein the ubiquitin protein ligase polypeptide is an SCF polypeptide, a HECT polypeptide, or a UBR1 polypeptide;
expressing said ubiquitin protein ligase polypeptide-target polypeptide interaction domain hybrid in a cell;
recruiting the target polypeptide to said ubiquitin protein ligase polypeptide; and
ubiquitinating the target polypeptide,
thereby forming a ubiquitin-target polypeptide conjugate which is targeted for degradation.

- B17
6. (Amended) The method of claim 1, wherein the SCF polypeptide is an F-box polypeptide.

- B18
11. (Amended) The method of claim 1, wherein the ubiquitin protein ligase polypeptide is an SCF polypeptide selected from the group consisting of: a Cdc4 polypeptide, a Skp1 polypeptide or a cullin polypeptide.

REMARKS

The above amendments enter no new matter. Support for the amendment to claim 1 can be found throughout the application, for example, in original claim 5, at page 178, lines 22-23. Applicants expressly reserve the right to pursue without prejudice the originally filed claims as well as other disclosed subject matter at a latter date.